Welcome to our dedicated page for Nexalin Tech news (Ticker: NXL), a resource for investors and traders seeking the latest updates and insights on Nexalin Tech stock.
Nexalin Technology, Inc. develops non-invasive neurostimulation products based on Deep Intracranial Frequency Stimulation, or DIFS™, for brain-health and mental-health indications. Company news commonly covers peer-reviewed clinical publications, neuroimaging and biomarker data, and research programs addressing insomnia, depression, traumatic brain injury, PTSD, Alzheimer’s disease, dementia-related cognitive decline and ADHD.
Updates also describe the HALO™ Clarity device, the NeuroCare® virtual clinic platform, collaborations with clinical research and academic organizations, FDA engagement, and capital-market communications tied to its Nasdaq-listed common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) provided a business update on March 27, 2023, highlighting progress in clinical trials for new neurostimulation devices aimed at treating mental health disorders. The Gen-2 and Gen-3 devices are expected to improve treatment efficacy without medication. Revenue for 2022 reached $1.3 million, a significant increase from $0.1 million in 2021, primarily due to more device sales. While operating expenses decreased to $2.8 million from $6.1 million, the net loss narrowed to $1.7 million per share. The company reports having $7.0 million in liquidity for future operations.